After successful expansion into North America last year, Airfinity is proud to be opening a new office in Japan to provide a formal base for its activities across the APAC region.

Japan office launch

Airfinity further expands into APAC with launch of Japan office

GLP-1 receptor agonist-based compounds are the most common drug class in late stage clinical trials

23 anti-obesity drug clinical trials will reach primary completion within the next 3 months

Airfinity has launched an obesity intelligence solution dedicated to the breakthrough obesity treatments market. 

Obesity platformGIF

Airfinity launches obesity intelligence solution to forecast and simulate obesity related outcomes

medications-1853400 1280

Expired Pfizer Covid antiviral drugs set to cost Europe $2.2bn, data shows

Airfinity is pleased to welcome Alexander Karle, former CEO of Evaluate Ltd, to its advisory board.

A Karle headshot small

Airfinity announces Alexander Karle, former CEO of Evaluate, as newest advisor

Deloitte Fast 50 2023

Airfinity wins Financial Times’ Tech Champions 2023

0F7A1677-Edit websize

Airfinity gives decision makers big picture on health

Airfinity is pleased to announce the appointment of Professor Henrik Sillesen, MD, DMSc as the company’s first Chief Medical Officer to drive further growth and innovation within our work within pre-emptive health.

Henrik Sillesen I

Airfinity appoints first Chief Medical Officer as part of increased pre-emptive health investments

Wegovy table

Screenshot 2023-08-30 at 09.40.28

Screenshot 2023-08-30 at 11.26.40

Airfinity has revised its cost effectiveness analysis for Wegovy, increasing the cost of preventing one heart attack, stroke or cardio vascular death from $1.1m to $1.3m.

jonnica-hill-V5nq6u-Ce U-unsplash

Wegovy costs $1.3m to prevent one heart attack, stroke, or cardiovascular death

jc-gellidon-xX0NVbJy8a8-unsplash

World Has 28% Risk of New Covid-Like Pandemic Within 10 Years

Newsroom

Featured